

## **The Ikoniscope20 preliminary results obtained with University of Connecticut School of Medicine (Neag Cancer Center of UConn) in detecting rare cells surpass the standards of test in immuno-oncology**

- **The Ikoniscope20 performs immune monitoring functions more effectively, easily and competitively than conventional flow cytometers (the standard tool used for such detection)**
- **The Ikoniscope20 detects rare cells at a superior rate to that provided by flow cytometers, also providing detailed morphology information thanks to its high-quality images**
- **Monitoring of immune responses in cancer patients is an increasing need because of newly approved immunotherapy treatments**
- **Those results pave the way for new opportunities for commercialization of the Ikoniscope20, as a better alternative than the flow cytometer**

**Paris, February 16, 2022 – 6:30 PM CET – Ikonisys SA (Code ISIN: FR00140048X2 / Mnemonic: ALIKO),** a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs, announced preliminary results of the sensitivity of the Ikoniscope20 to detect rare cells carried out in collaboration with the Carole and Ray Neag Comprehensive Cancer Center of the University of Connecticut (UConn) School of Medicine.

The Ikoniscope20 can detect as many as one positive cell among each 250 tested cells from mice immunized with ovalbumin (protein found in chick eggs). This frequency of detection is comparable or higher than that obtained by flow cytometry (the standard tool used for such detection).

Moreover, the Ikoniscope20 was able to detect as few as 1 positive cell among each 1,000 tested cells from un-immunized mice (specific T cell is expected to be even lower than in immunized mice). In contrast, standard flow cytometry could not detect them at all.

The Ikoniscope20 can compete with more costly flow cytometry instruments, and perform immune monitoring functions more effectively, inexpensively and easily.

Thus, it opens other commercialization opportunities of the Ikoniscope20 as a tool used by research laboratories for immune response monitoring. There is a fast-growing addressable market for monitoring newly approved immunotherapy treatments for cancer patients.

**Pramod Srivastava PhD MD, Director of the Neag Cancer Center:** *“The ability of the Ikoniscope20 to detect such rare cells should have a broad potential for applications in monitoring immune responses to cancers in experimental studies including monitoring of human cancer immuno-oncology trials, and is very exciting”.*

**Dr. Michael Kilpatrick, Chief Scientific Officer of Ikonisys,** added: *“We are honored to be working with a leading medical center to further demonstrate the potential of the Ikoniscope20 platform in the detection and quantification of specific populations of clinically relevant cells in immuno-oncology. These results open a new market opportunity for the Ikoniscope20 as an instrument of choice, for research laboratories dedicated to immuno-oncology, in addition to being an instrument of discovery in the field of circulating tumor cells”.*

## About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to [www.ikonisys.com](http://www.ikonisys.com)

## Contacts

---

### Ikonisys

Alessandro Mauri  
CFO  
[investors@ikonisys.com](mailto:investors@ikonisys.com)

### NewCap

Olivier Bricaud / Louis-Victor Delouvrier  
Investor Relations  
[ikonisys@newcap.eu](mailto:ikonisys@newcap.eu)  
Tel.: +33 (0)1 44 71 94 92

### NewCap

Nicolas Merigeau  
Media Relations  
[ikonisys@newcap.eu](mailto:ikonisys@newcap.eu)  
Tel.: +33 (0)1 44 71 94 98

## Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.